Gossamer Calls It Quits On BTK Inhibitor Following Patient Deaths

 
• By Alaric DeArment
Gossamer is prioritizing seralutinib in pulmonary arterial hypertension after deciding to discontinue GB5121 • Source: Shutterstock

More from Clinical Trials

More from R&D